公开(公告)号：EP3131896B1

公开(公告)日：2019-01-30

申请号：EP15779184.9

申请日：2015-04-10

Applicant: Merck Sharp & Dohme Corp. ,  Mochida Pharmaceutical Co., Ltd.

Inventor： SAKURADA, Isao ,  HIRABAYASHI, Tomokazu ,  MAEDA, Yoshitaka ,  NAGASUE, Hiroshi ,  MIZUNO, Takashi ,  XU, Jiayi ,  ZHANG, Ting ,  SMITH, Cameron ,  PARKER, Dann

IPC: C07D413/14 ,  C07D261/20 ,  C07D207/02 ,  A61K31/439

公开(公告)号：EP3131897A1

公开(公告)日：2017-02-22

申请号：EP15780578.9

申请日：2015-04-10

Applicant: Merck Sharp & Dohme Corp. ,  Mochida Pharmaceutical Co., Ltd.

Inventor： SAKURADA, Isao ,  HIRABAYASHI, Tomokazu ,  MAEDA, Yoshitaka ,  NAGASUE, Hiroshi ,  MIZUNO, Takashi ,  XU, Jiayi ,  ZHANG, Ting ,  SMITH, Cameron ,  PARKER, Dann

IPC: C07D413/14 ,  C07D261/20 ,  C07D207/02

CPC classification number: C07D413/14 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/52 ,  A61K45/06 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04 ,  C07D519/00

Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract translation: 在其许多实施方案中，本发明提供了由式（I）表示的新一类苯甲酰胺化合物或其药学上可接受的盐或溶剂合物，或包含一种或多种所述化合物或其药学上可接受的盐或溶剂合物的药物组合物，以及使用 所述化合物或其药学上可接受的盐或溶剂化物用于治疗或预防血栓形成，栓塞，高凝状态或纤维变性。

公开(公告)号：EP3131896A1

公开(公告)日：2017-02-22

申请号：EP15779184.9

申请日：2015-04-10

Applicant: Merck Sharp & Dohme Corp. ,  Mochida Pharmaceutical Co., Ltd.

Inventor： SAKURADA, Isao ,  HIRABAYASHI, Tomokazu ,  MAEDA, Yoshitaka ,  NAGASUE, Hiroshi ,  MIZUNO, Takashi ,  XU, Jiayi ,  ZHANG, Ting ,  SMITH, Cameron ,  PARKER, Dann

IPC: C07D413/14 ,  C07D261/20 ,  C07D207/02

CPC classification number: A61K31/439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07D209/52 ,  C07D261/20 ,  C07D413/04 ,  C07D413/14 ,  C07D498/04 ,  C07D519/00

Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract translation: 在其许多实施方案中，本发明提供了一类由式（I）表示的新型苯甲酰胺化合物或其药学上可接受的盐或溶剂合物，或包含一种或多种所述化合物或其药学上可接受的盐或溶剂化物的药物组合物，以及使用 所述化合物或其药学上可接受的盐或溶剂化物用于治疗或预防血栓形成，栓塞，高凝状态或纤维化改变。

公开(公告)号：EP2128157A1

公开(公告)日：2009-12-02

申请号：EP08710655.5

申请日：2008-01-24

Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.

Inventor： UCHIDA, Hideharu ,  OGAWA, Shinichi ,  MAKABE, Muneyoshi ,  MAEDA, Yoshitaka

IPC: C07D413/12 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5415 ,  C07D405/12 ,  C07D417/12

CPC classification number: C07D405/12 ,  C07D413/12 ,  C07D417/12

Abstract: The blow-described formula (I):
[Ch. 1]

a compound represented by formula (I) :

(wherein k, m, n, and p each represent 0 to 2; j and q represents 0 or 1; R 1 represents a halogen atom, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, NH 2 , OH, a carboxyl group, an alkanoyl group, CN, NO 2 , or the like; R 2 represents a halogen atom, an amino group, a hydrocarbon group, an aromatic heterocyclic group, an oxo group, or the like; X 1 represents an oxygen atom, -NR 3 -, or -S(O)r- (wherein r is an integer of 0 to 2); X 2 represents a methylene group, an oxygen atom, -NR 3 - (wherein R 3 is a hydrogen atom, a hydrocarbon group, or the like), or -S(O)r- (wherein r is an integer of 0 to 2); W represents a methylene group, a carbonyl group, or a sulfonyl group; R 7 represents a hydrogen atom, a hydrocarbon group, a heterocyclic group, or the like; R 8 represents a hydrogen atom, a halogen atom, a hydrocarbon group, a heterocyclic group, the broken line in the ring containing X 1 and X 2 represents a condensation of two rings; cycle moiety represents a five- or six-memebered aryl ring or heteroaryl ring; and the solid line and the broken line between L 1 and L 2 are a single bond or double bond, and the wavy line represents an E-isomer or a Z-isomer), a salt thereof, or solvates thereof, and a pharmaceutical composition containing the compound as an active ingredient.

Abstract translation: 吹制描述的公式（I）：[Ch。 1]由式（I）表示的化合物：其中k，m，n和p各自表示0〜2; j和q表示0或1; R 1表示卤素原子，烃基，杂环基， 烷氧基，烷氧基羰基，NH 2，OH，羧基，烷酰基，CN，NO 2等; R 2表示卤素原子，氨基，烃基，芳香族杂环基， 氧代基等; X 1表示氧原子，-NR 3 - 或-S（O）r - （其中r为0〜2的整数）; X 2表示亚甲基，氧原子 ，-NR 3 - （其中R 3为氢原子，烃基等）或-S（O）r - （其中r为0〜2的整数）; W表示亚甲基， 羰基或磺酰基; R 7表示氢原子，烃基，杂环基等; R 8表示氢原子，卤素原子，烃基，杂环基，虚线表示 该环包含X 1和X 2代表 表示两个环的冷凝; 环状部分表示五或六元芳基环或杂芳基环; L 1和L 2之间的实线和虚线是单键或双键，波浪线表示E-异构体或Z-异构体），其盐或其溶剂合物，以及药物组合物 含有化合物作为活性成分。